BC Week In Review | Jul 11, 2016
Clinical News

Nelipepimut-S: Phase III discontinued

Galena discontinued the double-blind, placebo-controlled, international Phase III PRESENT trial comparing intradermal NeuVax plus intradermal Leukine sargramostim vs. Leukine alone at an IDMC’s recommendation based on a planned interim futility analysis. Dr. Reddy’s has exclusive...
BC Extra | Jun 30, 2016
Clinical News

Galena plummets after halting NeuVax study

Galena Biopharma Inc. (NASDAQ:GALE) lost $1.68 (83%) to $0.35 on Wednesday after it said it will halt the Phase III PRESENT study of NeuVax nelipepimut-S at an independent DMC's recommendation based on an interim futility...
BC Week In Review | May 2, 2016
Clinical News

FBP vaccine: Additional Phase IIa data

Data from 17 HLA-A2-positive patients with endometrial or ovarian cancer who completed the Phase IIa portion evaluating 6 monthly injections of intradermal GALE-301 plus GM-CSF and continued to the booster series portion of an open-label,...
BC Week In Review | May 2, 2016
Clinical News

GALE-302: Additional Phase IIa data

Data from 17 HLA-A2-positive patients with endometrial or ovarian cancer who completed the Phase IIa portion evaluating 6 monthly injections of intradermal GALE-301 plus GM-CSF and continued to the booster series portion of an open-label,...
BC Week In Review | Jun 8, 2015
Clinical News

FBP vaccine: Additional Phase IIa data

Additional data from 51 HLA-A2-positive patients with endometrial or ovarian cancer in the Phase IIa portion of an open-label, U.S. Phase I/IIa trial showed that 6 monthly injections of 100, 500 or 1,000 ug intradermal...
BioCentury | Jun 8, 2015
Finance

ASCO's early returns

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing to...
BC Week In Review | Nov 17, 2014
Clinical News

FBP vaccine: Preliminary Phase IIa data

Preliminary data from the Phase IIa portion of an open-label, U.S. Phase I/IIa trial in 51 patients with ovarian or endometrial cancer showed that 6 monthly injections of 100, 500 or 1,000 ug intradermal GALE-301...
BC Week In Review | Aug 18, 2014
Clinical News

FBP vaccine: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in 30 HLA-A2-positive patients with endometrial or ovarian cancer showed that no recurrences have been observed in patients in the optimal dose cohort of 1,000...
BC Week In Review | Jul 14, 2014
Clinical News

FBP vaccine: Completed Phase IIa enrollment

Galena completed enrollment of 45 HLA-A2-positive or HLA-A2-negative patients with ovarian or endometrial cancer in an open-label, U.S. Phase IIa trial evaluating 1,000 Ug intradermal GALE-301 plus GM-CSF. Patients will receive an initial induction series...
BC Week In Review | Jan 13, 2014
Clinical News

GALE-301: Phase II started

Galena began an open-label, U.S. Phase II trial to evaluate GALE-301 plus GM-CSF in 30 HLA-A2-positive and 30 HLA-A2-negative patients with ovarian and endometrial cancer. Patients will receive an initial induction series of 6 vaccinations...
Items per page:
1 - 10 of 15